<unk> , formerly sold under the brand name Survector among others, is an atypical antidepressant of the tricyclic antidepressant (TCA) family. It acts as a selective and mixed dopamine reuptake inhibitor and releasing agent, and to a lesser extent as a norepinephrine reuptake inhibitor.<unk>  was developed by the French Society of Medical research in the 1960s. Introduced in France in 1978 by the pharmaceutical company Servier,<unk>  soon gained a reputation for abuse due to its short-lived, but pleasant, stimulant effect experienced by some patients. After its release into the European market, cases of hepatotoxicity emerged, some serious. This, along with the potential for abuse, led to the suspension of the French marketing authorization for Survector in 1999.<unk>  was never approved by the U.S. Food and Drug Administration (FDA) for marketing in the United States, meaning that it is not legal to market or sell<unk>  for any medical uses in the U.S.
Amineptine
Fluorodopa
Butriptyline
Galantamine
Protriptyline
Tianeptine
Amantadine
Bisantrene